CNS Pharmaceuticals, Inc.
NASDAQ:CNSP
6.39 (USD) • At close September 8, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | CNS Pharmaceuticals, Inc. |
| Symbool | CNSP |
| Munteenheid | USD |
| Prijs | 6.39 |
| Beurswaarde | 3,671,534 |
| Dividendpercentage | 0% |
| 52-weken bereik | 4.93 - 222 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. John Michael Climaco Esq., J.D. |
| Website | https://www.cnspharma.com |
An error occurred while fetching data.
Over CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)
